Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
artemether + lumefantrine
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04300309 CALINA (CCOA566B2307)
Malaria, uncomplicated (<5kg patients)
Phase 3
Artemether Cmax
-
PGH-1
Target Patients
Read-out Milesstone(s)
Experimental: artemether lumefantrine (2.5 mg:30 mg)
artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium
falciparum malaria
Primary outcome measure: 2023
Publication
TBD
134 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation